111P Proactive management of immune-related hepatic events in a phase II trial of acasunlimab plus pembrolizumab in patients with mNSCLC

Acasunlimab (Aca; DuoBody-PD-L1x4-1BB) is a bispecific antibody immunotherapy designed to reinvigorate antitumor immunity via conditional 4-1BB activation dependent on co-PD-L1 binding. A ph 2 study of Aca in patients (pts) with PD-L1+ mNSCLC (NCT05117242) showed an acceptable safety and efficacy profile. Given historical immune-related risks with 4-1BB agents, proactive management of immune-related risks (PMIR) was implemented. We report the effects of PMIR on mitigation and management of immune-related hepatic adverse events (IRHAEs).